home

Employee No. 1: Doug Williams launches exosome R&D player Codiak Bio with $80M-plus

CommentsJohn Carroll2015-11-18 14:05 Read   363

Doug Williams is now happy to reveal just why he stepped aside four months ago as R&D chief of Biogen ($BIIB).

Regeneron plots a $150M R&D expansion, adding 300 jobs at its New York hub

CommentsRegeneron2015-11-14 21:54 Read   209

Regeneron Pharmaceuticals ($REGN), riding high with a top-selling eye drug and some promising pipeline assets, is planning to invest $150 million in its native New York, supporting 300 new jobs at its fast-growing R&D campus.

Soon-Shiong's NantKwest is spending more on stock buybacks than R&D

CommentsNantKwest2015-11-14 00:07 Read   1203

NantKwest ($NK), an oncology biotech in Patrick Soon-Shiong's constellation of companies, made headlines over the summer when it pulled off a $200 million IPO that valued it at more than $2.5 billion. But the company's share value has slipped by nearly a third in the ensuing months, and instead of pouring money into developing its self-described breakthrough medicines, management has taken the uncommon tack of laying out $50 million to buy back stock.

Allergan delivers 'decent' Q3 sales growth, with price hikes driving half of it

CommentsAllergan2015-11-05 14:07 Read   478

All eyes are on Allergan's ($AGN) friendly deal talks with Pfizer, which is anxious to scoop up an acquisition and complete a tax inversion. But with the Irish drugmaker's execs mum on the possible combo Wednesday, the conversation turned to new product launches, drug pricing, and Q3 financials that looked "pretty good".

Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatient

CommentsFT story2015-11-04 11:15 Read   272

Bayer CEO Marijn Dekkers knows what it is to push it to the limit. But he also knows that too much pushing can take its toll.

Everybody's talking about the Pfizer-Allergan courtship. Here's the juiciest chat we overheard

CommentsPfizer2015-11-03 17:39 Read   304

Despite opposition from politicians, despite the tricky nature of pulling off a tax inversion that size, Pfizer ($PFE) and Allergan ($AGN) may well be engaged before the month is out, giving Pfizer its long-sought tax reduction and its answer to the who-will-you-buy question that's popped up on every earnings call since AstraZeneca's ($AZN) final rejection last year.

The top 10 biopharma pipeline disasters of 2015

Commentsfiercebiotech2015-10-30 13:17 Read   222

Drug R&D is a tough business. The odds are almost always against success, and the price to be paid for being wrong is cruelly high.

Strategic planning in pharma and avoiding frog soup

CommentsPmlive2015-10-25 19:46 Read   297

The secret of strategic planning in the pharmaceutical industry may come from asking the most unlikely of questions: has my brand team succumbed to the Parable of the Boiled Frog?

Cempra Antibiotic Hits Phase 3 Target, FDA Filing Planned

Commentswww.xconomy.com2015-10-19 19:28 Read   228

Cempra’s next-generation antibiotic, which has been touted as a potential blockbuster, is moving toward an FDA filing on news that the drug achieved positive results in a Phase 3 clinical trial.

FDA rejects AstraZeneca's diabetes combo and demands more data

CommentsPharmacodia.com2015-10-19 00:00 Read   227

 The FDA wants to see more clinical trial data on AstraZeneca's ($AZN) new combination diabetes treatment, the company said, likely delaying a potential launch by more than a year.

In pharma M&A, 2015 trumps red-hot 2014 so far, report says

CommentsPharmacodia.com2015-10-18 00:00 Read   382

Think last year was a hot one for pharma M&A? Just take a look at 2015, a new report says.

TPP Negotiations Resolved: Was It Really A Win For Global Biosimilar Market?

CommentsPharmacodia.com2015-10-14 00:00 Read   309

After a great amount of debate, the parties involved in hammering out biologics exclusivity rules in the Trans-Pacific Partnership (TPP) have finally settled on a deal. However, these final negotiations have garnered the ire of the pharmaceutical industry and nonprofit groups alike.